Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary
October 27, 2020
Earnings Call Speaker Segments
Peter Dannenbaum
executiveLaura, thank you, and good morning to everyone. It's a pleasure to have you all on this call for Merck's conference covering the third quarter of 2020. Joining me today are Ken Frazier, who serves as our Chairman and Chief Executive Officer; Rob Davis, our Chief Financial Officer; Dr. Roger Perlmutter, who is President of Merck Research Labs; Frank Clyburn, our Chief Commercial Officer; Mike Nally, our Chief Marketing Officer; and Dr. Dean Li, Head of Discovery Research. Prior to beginning, there are a few things I want to highlight. Among the items in our GAAP results, you'll notice things like charges tied to acquisitions, costs from restructuring, and certain other entries. Please be aware that these have been left out of our non-GAAP results, and a reconciliation appears in the press release we issued. Additionally, a table is included in that press release so you can better grasp the sales for the quarter across our business units and products. I also want to remind everyone that certain remarks we may offer today could fall under the definition of forward-looking statements, as described in the Safe Harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Those remarks reflect what Merck's management currently believes and carry substantial risks and uncertainties. Should our underlying assumptions turn out to be wrong or should uncertainties come to pass, actual results could differ materially from what those forward-looking statements describe. Our SEC filings, including Item 1A in the 2019 10-K, lay out specific risk factors and cautionary statements that might lead the company's actual results to diverge materially from any projections in the forward-looking statements we make this morning. Merck assumes no duty to publicly revise any forward-looking statements. All of our SEC filings, the earnings release issued today, and an investor presentation containing several highlights of our results can be found on merck.com; and now, I'd like to hand things over to Ken.
Kenneth Frazier
executiveThanks, Peter. Good morning, everyone, and thank you for being with us on today's call. To begin, I'd like to recognize the remarkable work being done by scientific experts throughout the biopharmaceutical sector, who are meeting this challenge head-on and devoting themselves tirelessly to discovering solutions that can help bring the pandemic to an end; our confidence remains firm that science will triumph over COVID-19, and Merck is dedicated to bringing its scientific know-how and resources to bear in support of these efforts around the globe. As we've noted, developing medicines and vaccines to tackle the pandemic demonstrates the societal worth of our industry's ongoing scientific investment, as well as the value of the women and men who are pursuing this with urgency and commitment. Given its lengthy and successful track record in antiviral and vaccine research, Merck bears a particular responsibility to put its expertise to use, and through concentrated investment of effort and resources we are pushing our vaccine and antiviral programs ahead; over the past few months we've achieved meaningful progress throughout our COVID program, and what we've learned strengthens our belief that the approaches we've chosen rank among those with the greatest promise. We're proceeding with speed and care, structuring our clinical trials so that success will give physicians and patients confidence that our candidates are safe, effective, easy to administer and distribute, and able to serve not merely millions, but billions of people. Although we recognize how important it is to move quickly given the pandemic, what we've learned from the natural history of other pandemic and epidemic viral illnesses advises us to pursue lasting solutions that can be rolled out globally both now and for generations to come; this is an exciting moment at Merck, and I take encouragement from our scientists' enthusiasm for the innovative research taking place in our lab, not only on the COVID front but throughout our extensive pipeline of promising medicines and vaccines in which we continue to invest. Our deep pipeline and the world-class scientific team at Merck Research Lab reflect the outstanding leadership and numerous valuable contributions of Dr. Roger Perlmutter, who will step down from his current position at the close of this year. I am thankful for the remarkable contributions Roger has made to science, medicine, and the health and wellbeing of people worldwide, and to all of us at Merck as well. Roger's legacy is a strong one, marked by historic breakthroughs in immuno-oncology and numerous other areas of medicine that have changed clinical practice and bettered patient outcomes. During his tenure, the company has obtained more than 100 regulatory approvals globally for its <<inaudible>> and vaccines, and he has renewed the future of R&D at Merck. Dr. Dean Li, who currently serves as Senior Vice President of Discovery Sciences and Translational Medicine, has been named to take over from Roger as Head of Merck Research Laboratories, effective January 01. I'm eager to welcome him onto Merck's senior leadership team. I have no doubt that Dean's expertise, his drive, and his experience — along with the way he deliberately chases emerging technologies and transformative discoveries — will assist Merck in successfully carrying out our wide-ranging portfolio through this crucial period, in pushing our scientific strategy forward, and in extending the considerable momentum within our pipeline. Turning now to how we did in the third quarter, we kept right on carrying out our strategic priorities, and once again we delivered revenue growth compared with a year earlier, even with certain continuing pandemic effects, plus exceptionally strong EPS growth. Significantly, we closed out the quarter with ongoing business momentum; we are operating at a high level, with minimal disruption as we produce, supply, and distribute our medicines, vaccines, and animal health products, and as our clinical trials proceed. Demand at the foundational level for what we sell stays strong around the world, which the gains we posted in oncology and animal health demonstrate; we also take encouragement from the rebound occurring in vaccines and in those portions of the portfolio hit hardest by the pandemic's effect on the delivery of healthcare. We are performing effectively in the marketplace to generate growth throughout our current portfolio and in our laboratory by pushing our innovative research programs ahead. Substantial new findings we have lately made public across multiple research fields, among them oncology, vaccine, HIV, and others, bolster our confidence in our capacity to bring new innovations to market and to maintain robust growth over the long term, and our financial strength likewise permits us to act on our capital allocation priorities, among them our continuing investments in internal R&D as well as external business development, for example the recent oncology collaborations with Teijin. Simultaneously, we are moving our plans forward to spin off Organon, which remains on schedule to be completed in the second quarter of 2021. We stay confident in our choice to form two more focused companies, each devoted to its own strengths and portfolios and better positioned to navigate a changing healthcare landscape and to increase value for patients and shareholders. We keep bringing on board talented, seasoned leaders who will assist in driving Organon's success as a standalone company. Allow me to finish by stating my confidence in the business and in our capacity to move our pipeline forward notwithstanding the difficulties the pandemic has created. In addition, I offer my heartfelt thanks to the frontline healthcare workers and to our employees who labored around the clock to assist patients suffering from COVID-19. Their commitment motivates everyone at Merck to stay devoted to our mission and to pursue innovative science without letup, so as to help get ready for the greatest health threat, both at present and going forward. With that, I will now hand the call over to Rob, who will go through the specifics of our performance and our outlook.
Robert Davis
executiveKen, thanks, and good morning to everyone. As Ken mentioned, we remain heartened by how robust and resilient the business is, since we once again achieved growth compared with a year earlier even with the pandemic's continuing effects. Across Merck, staff are carrying on their crucial work—advancing the pipeline and making sure patients can obtain our portfolio of medically important medicines and vaccines—while also pitching in on industry-wide efforts to find pandemic solutions. During the quarter, our performance and the underlying demand for products across our main growth pillars recovered strongly, bringing us to a very strong finish near the end of the year, as our updated guidance reflects. We keep carrying out our long-term strategy, which includes our capital allocation priorities. We are putting money behind our deep pipeline, our COVID candidates included, and we have stayed active on the business development side. Notably, in this quarter we completed a strategic collaboration agreement with Teijin, giving us access to two oncology assets that further bolster our pipeline. We are dedicated to long-term investment in our business, and we will keep doing that in keeping with our mission of following the science to address unmet needs for patients worldwide. Now let me turn to our third quarter results. Revenues for the total company came to $12.6 billion, which is up 1% versus a year ago, or 2% when you exclude the negative foreign currency impact. The pandemic hurt our third quarter human health results by roughly $475 million, chiefly within our vaccines portfolio. Animal health saw minimal impact. Without this estimated impact, our revenue growth would have been about 5%, or 6% ex exchange. The rest of my remarks will concentrate on the underlying performance of our key growth drivers and near-term trends, and they will be on an ex exchange basis. Our human health revenues rose 2%. In oncology, KEYTRUDA sales increased 21% compared with a year earlier, hitting $3.7 billion. Within the United States, growth in KEYTRUDA usage across all key tumor types stayed strong, and KEYTRUDA remains the leader in lung cancer by a margin that keeps widening. We are reinforcing our leadership in IO across a broadening array of indications beyond lung cancer, particularly in melanoma, bladder and head and neck cancers, with momentum from launches in renal cell and endometrial carcinomas. It is worth noting that indications outside of lung now account for approximately 50% of our sales in the United States and will keep growing over time as we further penetrate these indications and keep adding new ones going forward. Uptake following the launch of our q6 weekly adult dosing regimen helped to offset the impact of reduced new patient starts caused by the pandemic. Beyond the United States, lung cancer indications remain the driver of KEYTRUDA growth. In the EU, expansion is still being propelled by adoption of KEYNOTE-189 and KEYNOTE-407 in the first-line setting, where penetration remains robust; in Japan, the net effect of the two large seller pricing adjustments made during the first half of the year was more than enough to cancel out underlying volume gains. Lynparza and Lenvima keep showing impressive growth and stay significant contributors to our wider oncology portfolio, with year-over-year increases of 58% and 29%, respectively. Lynparza's results this quarter still mirror robust growth and leadership within the PARP class in the U.S. notwithstanding mounting competition, helped by incremental contributions from an expanded ovarian cancer indication and early launch uptake in prostate cancer. Lenvima holds market leadership in first-line hepatocellular carcinoma, and its combination with KEYTRUDA in endometrial carcinoma has become the top regimen for the metastatic setting in the United States. Now on to vaccines. As noted earlier, although our vaccines portfolio recovered strongly from the second quarter, year-over-year comparisons took a negative hit from persistently below normal wellness visit levels, especially in the United States. GARDASIL sales fell 10% year-over-year, since growth in markets outside the U.S. was largely canceled out by pandemic-related effects in the United States. Volumes during the crucial back-to-school period came in below normal, particularly for adolescents. Sales also took a hit from postponed public sector purchases. Outside the U.S., growth came from continued strong volume in China and the broadening of general neutral vaccination programs across Europe, partly offset by weaker demand in Hong Kong. PNEUMOVAX posted 58% growth, driven by greater awareness of how important protection against pneumococcal disease is amid the pandemic and as the flu season approached, which partly offset the GARDASIL decline. Although our vaccines business, GARDASIL especially, is always prone to quarter-over-quarter variability, longer term trends in underlying demand keep getting stronger. We stay confident about GARDASIL's future growth prospects given growing global recognition of its key role in preventing certain cancers, bolstered by recent data published out of Sweden. Our hospital performance also came in better than second quarter levels. Most notably, the rebound in elective surgical procedures lifted BRIDION, which grew 13% year-over-year. Our ongoing PROVAMES launch also helped, growing 69%. Our human health business has kept climbing, reaching sales of $1.2 billion and delivering 12% growth year-over-year. Companion animal rose 18%, reflecting underlying demand for the BRAVECTO line of products and strength from our portfolio of companion animal vaccines. Livestock rose 8%, reflecting contributions across our ruminants line and poultry products as well as growth from our technology products. We take encouragement from the resilience of our animal health business, which has exceeded our expectations in this challenging environment. Now turning to the rest of our P&L, my comments will be on a non-GAAP basis. Gross margin came in at 74.8% for the quarter, down 110 basis points, driven by a mix of pricing pressure, inventory write-offs, collaboration amortization and foreign exchange, partly offset by product mix. Operating costs came down 6% compared with a year earlier, landing at $4.5 billion. All told, COVID gave us a favorable swing of about $115 million in spending, mostly because promotional, selling, and administrative costs were lower, and lab, travel, and meeting expenses also fell, though that was partly offset by more spending to push forward our COVID-19 antiviral and vaccine research programs. The big year-over-year jump in other income came from unrealized gains on our security holdings, mainly reflecting our direct and indirect investments in Moderna. Our effective tax rate for the quarter was 14.8%, and that came from a lower assumed full year effective tax rate thanks to a favorable earnings mix. Put it all together, and we earned $1.74 per share, up 18%, which shows strong operational performance that more than offset COVID headwinds, plus the boost from our other income. Now, on to guidance — our updated guidance shows our confidence in the underlying strength of our business. We now expect revenues of $47.6 billion to $48.6 billion, which is an increase of $150 million from our previous midpoint. Our guidance assumes roughly $2.35 billion of COVID headwind for the year, up from our prior assumption of $1.95 billion. We now assume a negative impact from foreign exchange of roughly 1.5 percentage points using mid October rates. Overall, our guidance implies 3% to 5% growth in revenues for the full year excluding the impact of exchange.
Robert Davis
executiveIf we set aside the pandemic's effects, the range we're guiding to suggests an 8% to 10% increase compared with a year earlier, which speaks to demand for our products that stays strong at its core. On the whole, the way our business has bounced back is encouraging, and it has mostly matched what we initially expected, though GARDASIL stands out as the main exception. GARDASIL is moving in a favorable direction, yet the recovery's timing is unfolding more slowly than we had projected, chiefly because of how the pandemic affected the back-to-school period, especially in the United States. We're additionally observing lingering negative consequences from the pandemic carrying over into the fourth quarter, along with certain regions of the world, mainly Europe and a number of emerging markets. Above all, our operational results stayed solid, which let us counterbalance the pandemic's effects. As the year closes and we move toward 2021, our confidence gains further support from how healthcare systems globally have managed to adjust and provide care, and from the worth of our medically important products as delivered to patients. Consequently, we remain convinced about our long-term growth potential, which the Street still undervalues. We still anticipate gross margin at approximately 75%. Operating expenses are now projected to fall at a low single digit rate compared with a year earlier, thanks to lower spending brought on by the pandemic and disciplined expense management. We now project our full year tax rate at 15.5% as a result of a better earnings mix; we now project other income at approximately $750 million as a result of greater income from investments in equity securities. We still expect 2.54 billion shares outstanding. All told, we now project our non-GAAP EPS in the range of $5.91 to $6.01, an increase of $0.25 relative to our prior midpoint. This range incorporates a negative foreign exchange impact of approximately 2.5 percentage points. Our results keep gaining from a better tax rate and greater other income stemming from gains on our equity holdings. Even so, our operational strength keeps generating leverage in the P&L via strong revenue growth and expense management, which permits significant investments in our pipeline while simultaneously producing margin expansion. We keep advancing our strategy to transform our operating model so that efficiency and productivity improve across the organization. This is happening via process improvements and by capitalizing on new digital capabilities, which matter more and more as we discover fresh approaches to connecting with patients and physicians during this pandemic. Our balance sheet stays solid and we are positioned well to carry out our capital allocation priorities. Putting full investment behind our key growth drivers and pipeline stays our foremost priority, and we are dedicated to raising the dividend and to pursuing value enhancing business development that will assist in positioning Merck for long-term success. In closing, the rapid recovery we saw in the third quarter signals the genuine value our products bring to patients worldwide and our capacity to execute. Our business's underlying strength still gives us great confidence, and there's a substantial runway for growth thanks to the risk-reduced asset portfolio we hold. Additionally, when Organon is spun off during the second quarter, it will be positioned to capture the growth potential within its lineup of medically important products, and it will let us direct our focus and investments more completely toward our main growth drivers and strong pipeline, so we can bring innovative medicines and vaccines to patients across the globe today and well into the future. Before wrapping up, I want to express my own thanks to Roger for everything he has contributed to Merck, which will serve our company and the patients we serve for many years ahead. Working beside you and learning from you has been a pleasure. With that said, I'll hand the call over to Roger.
Roger Perlmutter
executiveThanks a lot, Rob. Over the course of Q3, significant progress was achieved by our labs across numerous areas — among them securing regulatory clearances, submitting applications for new medicines, generating valuable fresh clinical evidence, moving promising new product candidates into development, and establishing additional R&D partnerships. A number of these achievements are itemized in our press release, yet that document is unable to capture how quickly these programs are moving forward. To illustrate, in Q3 the United States Food & Drug Administration granted approval for a broader label covering KEYTRUDA for relapsed or refractory classical Hodgkin lymphoma, drawing on findings from our KEYNOTE-204 trial, which pitted KEYTRUDA monotherapy against brentuximab vedotin, a standard therapy. But remember, the clearance for this indication arrived only three months after acceptance of the filing — which speaks to how excellent the work from our clinical development and regulatory teams has been. Also, reviews are underway for KEYTRUDA in the first line setting, paired with chemotherapy, for patients with previously untreated locally recurrent inoperable or metastatic triple negative breast cancer whose tumors express PD-L1 with a combined proportion score of 10 or higher; the KEYNOTE-355 study provides the supporting data, and the PDUFA date is November 28. Reviews are also ongoing for triple negative breast cancer in the neoadjuvant and adjuvant settings, based on findings from KEYNOTE-522, with a PDUFA date of March 29, 2021. Findings from these trials have already been shared. Over in Europe, positive recommendations were adopted by the Committee for Medicinal Products for Human Use, or CHMP, for Lymparza as a monotherapy in treating patients who have metastatic BRCA mutant, castration-resistant prostate cancer and whose disease has progressed after treatment with a modern androgen blocking agent. A favorable opinion was also granted to Lymparza for first line maintenance treatment, combined with bevacizumab, of advanced homologous recombination deficient ovarian cancer, on the basis of results from the TOWER I <<inaudible>> Phase 3 study. In the meantime, approval was secured in Japan for KEYTRUDA in second line treatment of PD-L1 positive esophageal cancer, drawing on data from our KEYNOTE-181 study. Also, Japan has now cleared the 400 mg dose given every six weeks for KEYTRUDA across all adult indications — the same schedule patients in Europe and the U.S. already have access to. The reason I call out these clearances is that they show how our broad registration efforts for KEYTRUDA keep building momentum, and so does our worldwide collaboration with AstraZeneca on Lymparza, even with the obstacles the COVID-19 pandemic has put in the way. During the European Society for Medical Oncology gatherings in the first part of September, we presented long-term findings that show how KEYTRUDA keeps working against cancer over time. Take, for instance, findings from KEYNOTE-024, our trial in first-line therapy for non-small cell lung cancer among individuals whose tumors had PD-L1 expression on 50% or more of tumor cells. Those results demonstrated that at the five-year mark, overall survival came close to doubling among those given KEYTRUDA versus patients treated with conventional chemotherapy — and this happened even though a large proportion of the chemotherapy group crossed over to receive KEYTRUDA. Also, when we looked at combining chemo with KEYTRUDA versus chemo alone, the KEYNOTE-048 study showed a real improvement in how long patients lived overall at the 4-year mark for squamous cell carcinoma of the head and neck — especially for those whose PD-L1 expression combined proportion score was greater than 1. And in melanoma, when given as adjuvant treatment following surgery, the longer-term data showed a 40% reduction in the chance of distant metastases among people who got KEYTRUDA, compared with those given no adjuvant therapy. All of this together shows that the outcome improvements hold up over time, which speaks to the work of applying KEYTRUDA to cancers that are otherwise difficult to manage. At ESMO 2020, we additionally shared results on possible new cancer treatments, among them vibostolimab, our anti-TIGIT antibody, which we hope could boost treatment responses when given alongside KEYTRUDA in non-small cell lung cancer patients whose tumors have low PD-L1 expression, including those whose disease has progressed after prior checkpoint inhibitor therapy. Vibostolimab ranks among three new agents we have selected for priority development in combination with KEYTRUDA, and we intend to move this agent into pivotal trials during 2021. We also shared results for MK-4830, an ILT4 antibody that works by blocking immune suppression driven by components of the tumor microenvironment. MK-4830 demonstrated encouraging activity across multiple tumor types, including among patients whose tumors had progressed on PD-L1 therapy. We're continuing to run expansion cohorts that will look at MK-4830 in pancreatic adenocarcinoma, glioblastoma, head and neck cancer, advanced non-small cell lung cancer, and gastric cancer. Then, quite recently, during the North American conference on lung cancer, we presented data involving our novel CTLA-4 directed therapy, quavonlimab, given at 25 mg once every six weeks in combination with KEYTRUDA for first-line non-small cell lung cancer. After a median follow up of 16.9 months, the findings showed an overall response rate of 37.5%, and median overall survival came in at 18.1 months. Of note, among those who responded, median duration of response had not been reached. A registration enabling study that looks at quavonlimab co-formulated with KEYTRUDA is planned for 2021. During Q3, we advanced a number of additional novel drug candidates spanning multiple therapeutic areas. As an example, we provided additional data regarding how well MK-6482, our HIF-2 alpha inhibitor, performs in von Hippel-Lindau disease. We showed that tumors in the kidney shrank when patients received MK-6482, and the overall response rate — including confirmed responses only — was 36.1%. For pancreatic lesions tied to this disease, the confirmed overall response rate was 63.9%. In the case of central nervous system hemangioblastomas, the confirmed overall response rate reached 30.2%. That's a strong set of results, especially when you consider that today's standard of care for von Hippel-Lindau disease means patients must undergo surgical removal of tumors, often requiring dozens of operations stretched across many years. Turning to infectious disease, we're continuing to move islatravir forward — our first-in-class non-nucleoside reverse transcriptase translocation inhibitor designed for once-daily use alongside PIFELTRO. The 96-week Phase 2B data we presented at the HIV Glasgow conference showed treatment-naive patients maintaining viral suppression, a promising sign for where this regimen is headed. Enrollment in Phase 3 trials got underway in February of this year. We've also pushed ahead with MK-8507, a novel long-acting non-nucleoside reverse transcriptase inhibitor that we see as a strong match for islatravir in extended-dosing combinations. At the same time, we shared favorable immunogenicity findings from four more Phase 3 trials of V114, our 15-valent pneumococcal conjugate vaccine, when given to adults. Those results allowed us to finish the full collection of adult registration studies, and we'll submit that filing before this year ends. Also, in Q3, we achieved considerable headway on our programs aimed at COVID-19. Let's begin with molnupiravir—previously called MK-4482—an orally bioavailable direct-acting antiviral we're working on alongside Ridgeback Biotherapeutics. During Q1, we wrapped up Phase 1 trials, and the data showed this compound was well tolerated when given alone—both as a single dose reaching up to 1.6 grams, and as repeated dosing at 800 mg taken twice daily across five days. Our view is that the levels of the active <<inaudible>> in those who received treatment ought to be well beyond what's needed to shut down viral replication.
Roger Perlmutter
executiveOur partners at Ridgeback kicked off three fairly modest Phase 2 dose escalation trials looking at how molnupiravir fights the virus in people with COVID-19, and results from those trials should be out shortly. In the meantime, we've launched two sizable worldwide Phase 2/3 trials — one involving patients who are hospitalized, and the other involving outpatients. When combined, these trials will bring in over 2700 participants and will look at clinical outcomes, covering both how well the drug works and how safe it is. Given how the drug acts, we hold out hope that this new treatment, taken by mouth as a capsule, will substantially lower illness and death among those with COVID-19. Beyond that clinical progress, we've obtained the means to manufacture millions of molnupiravir doses prior to the close of 2020, with an even bigger supply set to arrive in early 2021. Worth noting is that in preclinical work, molnupiravir shows activity against many coronavirus types, among them the ones behind SARS and MERS, plus a broad range of RNA viruses, influenza virus included. So molnupiravir may turn out to be a valuable antiviral option across many different situations. Our vaccine candidates aimed at COVID-19 likewise moved into clinical trials in the third quarter. As Ken said, when it came to creating a COVID-19 vaccine, we stuck with platforms that are already proven, zeroing in especially on a replicating virus vector capable of delivering lasting protection after just one dose. The first of our vaccine candidates, created alongside the Institut Pasteur in Paris, relies on a modified measles virus vaccine that's been designed to express SARS-CoV-2's major surface protein. In the third quarter, this candidate, V591, moved into two Phase 1 clinical trials with close to 300 healthy volunteers taking part. Enrollment in the V591 Phase 1 trials has gone well, meaning immunogenicity findings ought to be ready before 2020 ends. A second candidate, V590, built together with the International AIDS Vaccine Initiative, or IAVI, uses a vesicular stomatitis virus vector — the very same vector system behind Ervebo, the first vaccine that successfully prevented Ebola virus disease. The Phase 1 effort for V590 is moving ahead much like the one for V591, though shifted by a few weeks. Once again, we feel optimistic that this candidate vaccine will trigger lasting immune responses against the SARS-CoV-2 spike protein after a single dose, and that it will prove safe and well tolerated. For V590 as well as V591, we're building facilities that will let us turn out many millions of vaccine doses soon, and hundreds of millions of doses if they're needed down the road. We expect these vaccines will come in a format allowing worldwide distribution with proper Cold Chain Management, ideally at refrigerated temperatures. Our earlier work creating vaccines for numerous other viral diseases gives us a measure of confidence that we'll manage to make an effective agent for prophylaxis against COVID-19. I want to direct everyone's attention here to some fresh findings that came out in the New England Journal of Medicine at the start of October, drawing on Swedish registries of demographics and health that track medical information for every person living in Sweden. This research looked at 1.67 million girls and women between 10 and 30 years old, assessed from 2006 through 2017. Within that population, once every covariate had been accounted for, immunization with GARDASIL prior to turning 17 produced an 88% drop in cervical cancer risk. These fresh results give us hope that this illness might one day be wiped out — one that, as the World Health Organization reports, takes the lives of over 300,000 women annually. This new Swedish research gives added momentum to what we are doing to scale up manufacturing of GARDASIL 9, aiming to make sufficient quantities of the vaccine — roughly 200 million doses annually — so that girls and boys everywhere can be vaccinated successfully. Last of all, I want to say thank you to my colleagues across all of Merck, and in particular those at the Merck Research Laboratories, alongside whom I have worked intermittently since 1996. It has been an honor to stand with all of you in turning breakthrough science into therapies that better and lengthen lives. Your achievements in creating new vaccines such as GARDASIL 9, innovative antibiotics, novel antivirals, fresh cancer-fighting treatments, medicines that enhance results for heart failure patients, and others bringing hope to people dealing with metabolic conditions and chronic debilitating syndromes — those achievements have not just improved and extended life, they have inspired the world. As I get ready to take on an advisory position at Merck, I have full confidence that Dean Li, the person who will follow me as President, is thoroughly ready to steer MRL toward even bigger accomplishments; we have arranged a smooth leadership handover, committed to guaranteeing — echoing George W. Merck — that human life will gain yet greater freedom from suffering and disease. I will now hand the call to Peter.
Peter Dannenbaum
executiveThanks, Roger. Laura, could you please put together the line for questions? Also, I want to request that the analysts on today’s call each stick to a single question; we’re aiming to wrap up exactly at nine, since I realize there are other calls you’re hoping to join.
Steve Scala
analystThanks, and it's hard to stick to just one question, but I'll do it. Can — under your leadership, Merck has changed dramatically. Following Dr. Perlmutter's retirement, I wanted to point out that I think two years ago, can you agree to stay on past 2019? May I ask if you will remain as Merck's CEO past 2021 to oversee this further transformation the company is pursuing? Thank you.
Kenneth Frazier
executiveThanks, Steve. The Board will keep assessing when CEO succession should occur at this point. No set timeline exists for CEO retirement. What I can say is I'm confident we have strong internal candidates to step into this role, and I look forward to collaborating with the Board to actively examine our leadership and succession planning and to make sure we have an orderly transition when the Board considers it suitable.
Peter Dannenbaum
executiveThanks, Steve. Can we take the next question?
David Risinger
analystSure, many thanks. First, I'd like to congratulate you, Roger, and express gratitude for everything you've brought, which includes changing how cancer is treated for patients around the globe, and your efforts will be missed. My question then is about the Phase 2 oral antiviral data from Ridgeback — could you share additional detail regarding the way you anticipate that data being communicated and what your focus for it would be? Thank you.
Roger Perlmutter
executiveMany thanks, David. Right, the Phase 2 studies conducted in the United States and the UK are fairly small, and their focus is on neurological endpoints; meaning grasping decreases in viral load along with decreases in virus infectivity from samples taken from patients. Regarding these data, my hope is that as enrollment finishes — and these are dose escalation studies — data will emerge from these studies across the coming 2 months; and after those data get reviewed, and sufficient data have built up, then presumably we'd issue a top line statement regarding those data. Naturally, though, the complete scientific results will come out in publication soon after. We'll definitely proceed swiftly since, naturally, we're aware the world holds great interest in this, just as we do.
Peter Dannenbaum
executiveThanks, David. Could we take the next question?
Tim Anderson
analystThanks. My question concerns KEYTRUDA and the adjuvant setting. In the past, Astra said there was a delay to when their adjuvant lung trial would read out, since the ADAURA findings made it necessary to adjust the design for EGFR positive patients receiving Tagrisso; and my assumption is that this will also affect adjuvant lung trials at other companies. Could you say something about when we might see the first readout from your adjuvant lung study? And looking more broadly at adjuvant, when should we expect your next adjuvant readout? Thank you.
Roger Perlmutter
executiveI apologize.
Kenneth Frazier
executiveYes, go ahead. Roger, please.
Roger Perlmutter
executiveRight. Our adjuvant trials in non-small cell lung cancer are moving forward on schedule, and right now we aren't conducting any review of those trials. Once again, it's hard to say precisely when the trials will report results, since we're obviously accruing events. Still, we expect the first of the adjuvant lung studies to be available at some point later next year, which is what we're hoping for, though only time will reveal.
Peter Dannenbaum
executiveThanks, Tim. Could we have the next question?
Chris Schott
analystThanks a lot, and Roger, I wish you the best in whatever comes next, plus congratulations for everything you've achieved across the years. I wanted to ask about GARDASIL here in the U.S. What's your view on what will be required before results in this market return to a typical pattern? I suppose what I'm really asking is whether we have to hold out for one more back-to-school period before that happens, or whether you believe the trends could begin moving back toward usual levels even with COVID around the way it is right now. And once things do settle down, should we expect some kind of catch-up bolus among the patients who didn't get their shot this year, or will it simply return to the customary cadence we've seen historically for that vaccine? Many thanks.
Kenneth Frazier
executiveFrank?
Frank Clyburn
executiveAbsolutely. Hello, everyone — Frank here. When it comes to GARDASIL's performance in the United States, I'd like to address the latter portion of your inquiry first, specifically about catch up. It's our expectation that catch up will gradually materialize. Specifically, by ramping up our commercial activities, particularly to ensure the adolescent group understands how critical vaccination with GARDASIL is, that's what we intend to do. On the question of timing, my view is that the back-to-school period, as we move into '21, will matter a great deal. To offer a bit more context on the U.S. situation, well visits among adolescents dropped roughly 30% relative to three-year historical averages. As Rob said, a more favorable trend is emerging, even if it falls short of our expectations. So over the coming several quarters, we'll need to observe how this develops, yet our confidence in GARDASIL's growth in the U.S. and worldwide remains very high. Regarding what Rogers brought up, the data from Sweden carries real significance, and in my view it underscores how vital the opportunity to prevent cervical cancer is for girls and boys across the globe. We likewise witnessed continued meaningful expansion in China, Germany, and numerous markets outside the U.S. So my take is that we will certainly be watching the next couple of quarters, but our belief in GARDASIL over both the medium and long term is still extremely solid, and we continue to feel very good about the product's overall demand outlook. Thank you.
Peter Dannenbaum
executiveI appreciate that, Chris. Could we move on to the next question?
Mara Goldstein
analystThank you very much for fielding this. I'd like to focus on the COVID vaccine program — could you perhaps walk us through the clinical program while keeping in mind the readouts still pending from other vaccines, as well as any contingency planning, so we can be confident those trials will fill up on schedule?
Roger Perlmutter
executiveYes, thank you, Mara. Naturally, it's extremely hard to predict what other studies are going to show. We share the general hope that numerous vaccines will produce positive results — fewer cases of illness and, ideally, fewer deaths tied to COVID-19 infection — and only time will reveal that. Yet the truth is, by the close of the year we'll have what we anticipate will be fairly robust immunogenicity data from a single dose, and we possess well designed Phase 2/3 protocols ready to launch at that moment. These are worldwide protocols, and my expectation — sadly, because the pandemic has hit so enormously hard — is that filling those studies quickly would not prove difficult, exactly as occurred with the other trials run using, say, the mRNA vaccines or the virus vaccines. So I'm unsure there's much to address there, other than that we're keen to see the data, same as everybody else, and we sincerely hope for efficacy along with a favorable safety profile.
Peter Dannenbaum
executiveThanks, Mara. Could we take the next question?
Umer Raffat
analystHello, and I appreciate you taking my question. Roger, regarding the COVID antiviral, I saw there was a committed Phase 1 and Phase 2 study looking at viral clearance. But as we approach the two Phase 3 trials that are now visible online, viral clearance doesn't appear to be the primary endpoint, nor even a secondary one, at least not in clean trials; and I also heard you reference favorable safety; so I just want to clarify, do you anticipate a viral clearance advantage? And how do you expect efficacy to differ or resemble what has been observed with Remdesivir thus far?
Roger Perlmutter
executiveYes, and I appreciate the question very much. Honestly, my expectation is that viral clearance will improve, and that view rests on many different inputs along with the drug's basic mechanism. When it comes to lowering viral burden, I believe it's quite probable that won't show up—they will be better than Remdesivir according to preclinical work. Naturally, that must be proven in the clinic, yet we'll have a substantial amount of Phase 2 virologic data from the <<inaudible>> studies, which were of course closely tied to the dose escalation work. Viewed in one way, from the start, this illness is driven by the virus. Eliminate the virus, and you ought to eliminate the illness. The real question is whether you can intervene soon enough and whether the effect is potent enough. Fortunately, this drug is taken orally. In principle it might be provided to people who are either showing symptoms or who have had contact with those infected by the virus. Yet to expand its use, we must establish both pre-clinically and clinically that giving the drug is safe for individuals who are otherwise healthy and merely at risk; so that is truly what concerns us when we discuss safety, and we are awaiting further data from additional subjects who have received the drug. It has been administered as a five day regimen and in several hundred people so far it appears to be very well tolerated. At this moment we know of no safety signals whatsoever for the drug. So we will simply wait and see. That is, after all, the crucial information we require.
Peter Dannenbaum
executiveThanks, Umer. Could we take the following question?
Gregg Gilbert
analystThanks, and I wish you both the best in whatever comes next, Roger and Dean. My question concerns V114 — it's perhaps partly about R&D and partly about marketing. Beyond any scheduling edge you may hold relative to Pfizer, especially in pediatrics, how do you see yourselves capturing a substantial portion of this market over the long run if Pfizer manages to bring its 20-Valent product to market successfully? A lot of investors seem to treat this space as one where the victor takes everything. I believe you've said things suggesting otherwise, so maybe you could elaborate on how that outcome might actually be realized? Thank you.
Kenneth Frazier
executiveMike Nally?
Michael Nally
executiveThank you for asking that. In examining the marketplace, the initial and primary thing we focus on is confirming that we truly deliver coverage against the 13 serotypes shared with PCV13; and I believe what we've managed to show in the Phase 2 data that you've reviewed among pediatric patients is that a strong immune response appears across those 13 shared serotypes. And that occurs following the third dose, which I consider another significant element, since finishing the primary series is genuinely a key moment. As for what comes afterward, the issue becomes how we extend beyond those 13 shared serotypes. And with our program, we've demonstrated a strong immune response for 22F and 33F, plus a very strong response for serotype 3, which is a major contributor to residual disease. So I think when we consider the genuine work on V114, it has always centered on ensuring we deliver the appropriate degree of protection among the core serotypes, and then extend to all the serotypes. I believe the matter of the first year of life will also prove significant. And we're eager to see additional data from our program along with Pfizer's program.
Peter Dannenbaum
executiveThank you, Gregg. Can we go to the next question?
Navin Jacob
analystHello, and thanks for taking my question. I'd also like to congratulate Roger. Roger, I'm curious whether you believe it's realistic for a COVID vaccine — yours in particular, but also in general — to deliver sterilizing immunity. Clearly, most trials right now are centered on symptom reduction, yet with all the talk about herd immunity and how crucial it is for fully reopening the economy, what are the implications if vaccines can't bring about a meaningful decrease in infection?
Roger Perlmutter
executiveYes, alright, and thank you for asking. Above all else, I believe what we seek from a vaccine is prevention of clinical disease. None of us, I think, would be especially troubled if people got infected but came down with no illness at all. If only we could ensure that outcome — naturally, that would require immunizing a sufficient number of people. My sense is that sterilizing immunity is going to prove hard. Given how things work with these respiratory infections, blocking any viral colonization is simply difficult. That's going to be a real challenge. Still, honestly, our understanding of COVID-19 and of SARS-CoV-2, the agent that causes it, remains at an early stage. So there's a great deal we don't yet grasp about the dynamics of this virus. As for the immune response's state during natural infection, and how long that protection lasts — whether from natural infection or, as we hope, following immunization — yes, there is much we need to investigate. What is evident is that, at minimum in uncommon instances, people who were infected and then cleared it are able to become infected again, and all of us ought to take that as a warning. With time, things might develop in a way that means a vaccine must be given again to stop disease from flaring back up following exposure to the virus, or perhaps we'll manage to keep it in check with just one dose, which is obviously our hope. My view is simply that such knowledge isn't available to us at present, and we'll gain a great deal of understanding in the coming months as more data emerge.
Peter Dannenbaum
executiveThanks, Navin. Could we take the next question?
Geoff Meacham
analystMorning, everyone. Appreciate the question. Roger, congratulations on your retirement. Working alongside both of you at Merck, and during your Amgen years, has been a real pleasure. My question concerns molnupiravir — I was hoping you might share additional Phase 1 specifics, things like common AEs or SAEs? And since it's taken orally, it really appears well matched to patients who are newly infected but have mild disease. I'd like your view on that. Thank you.
Roger Perlmutter
executiveSure, Geoff. Many thanks. Yes, regarding molnupiravir — once more, among the modest number of participants who got the drug during Phase 1 trials and who are now enrolled in Phase 2 trials, tolerability appears excellent across a 5-day course of b.i.d. dosing, at levels considerably exceeding what we think is needed to halt viral replication, or in fact to bring about aero catastrophe and basically clear the virus. So everything there looks, looks pretty favorable. As you noted, since the drug is given by mouth, in principle, with all else held equal, it might even be given prophylactically to people at elevated risk. Right now, we await further data, because as I mentioned, the drug is Ames-positive in a bacterial mutagenesis assay, and while it didn't score in eukaryotic micronucleus assays, and other grounds exist to think that won't pose an issue. Even so, we're running a wide range of studies examining immunogenicity. If those studies come back negative, then I believe we could consider prophylactic use far more broadly. Currently, our focus is chiefly on the setting where benefit-risk is plainly greatest — namely infected individuals, especially those with symptoms early in the disease course, an optimal setting for an orally given drug to blunt the impact of that infection.
Peter Dannenbaum
executiveThanks, Geoff. Could we take the next question?
Terence Flynn
analystHello, and thanks for fielding this. Best wishes to you, Roger, and gratitude for all your contributions to this area. Your team is moving a co-formulation combining KEYTRUDA with your CTLA-4 agent into Phase 3 for lung cancer. I'm curious how wide your approach to co-formulation goes, and whether it might also be feasible to co-formulate KEYTRUDA alongside your anti-TIGIT. Appreciate it.
Roger Perlmutter
executiveIsn't that so? The truth is, checkpoint inhibitors have occupied us for quite some time, just as they have many other groups, and specifically KEYTRUDA—though PD-1 targeted treatments in general produce quite striking, readily observable effects. Our hope has been to discover an option superior even to KEYTRUDA, yet neither our team nor anyone else has managed to identify one. It pleases us that our agents show activity when given alone, but that activity remains modest; it doesn't match what KEYTRUDA does, and the strongest impact appears when they're combined with KEYTRUDA. Thus it stands to reason these should be given alongside KEYTRUDA. There you'll observe the greatest advantage, and that's where co-formulation becomes feasible. That represents, in a sense, the perfect scenario. That's what we'd pursue, since a single dose would then deliver both medicines, provided no meaningful safety toll is added; accordingly, we've run our trials and are examining such questions. Obviously, for our CTLA-4 directed treatment this is highly logical, yet it's equally logical for every agent under our review, and we're evaluating both physical compatibility for co-formulation and whether it holds up from a clinical standpoint. In cases where it does, that's essentially the correct course for patients.
Peter Dannenbaum
executiveRight, thank you Terence. Next question, please?
Seamus Fernandez
analystMany thanks, and Roger, I wish you all the best — it has been a pleasure collaborating with you across these past several years. There's a commercial matter I'd like to raise; we're beginning to observe considerable promotional push from other drugmakers aimed at fueling a rebound in growth and a comeback to doctors' offices, particularly when it comes to primary care appointments, and clearly that has an effect on diagnosing illness. I'm simply curious about what Merck is doing commercially, and what it views as required to genuinely set us back on the proper path during 2021? How much of that is showing up in your business, and what steps are you taking to generate growth in '21?
Frank Clyburn
executiveYes, hello Seamus, Frank here. That strikes me as truly significant, and we're investing a great deal of energy. As you might expect, many of those efforts at present continue to be carried out in a virtual manner, particularly across various markets worldwide. Yet when you examine our actions, especially within the vaccine segment, I believe you might have come across some of our unbranded commercial initiatives meant to boost awareness regarding how important HPV vaccination is. You're able to see that we keep dedicating substantial effort to KEYTRUDA alongside healthcare professionals, and also through our consumer campaigns and initiatives. Beyond that, in numerous markets globally, we remain involved in educational programs designed to ensure physicians stay thoroughly informed about much of the fresh data you heard Roger discuss here this morning. So we have substantial undertakings worldwide, which is precisely why we feel confident about our broader growth trajectory, as we set our sights on both the remainder of this year and our entry into 2021.
Peter Dannenbaum
executiveAppreciate that, Seamus. And thanks to everyone for sticking to a single question. Really good questions. I'll hand things over to Ken now for some closing remarks.
Kenneth Frazier
executiveAppreciate that, Peter. As everyone just heard, our confidence in the strategy hasn't wavered at all, and the possibilities sitting in front of us have us quite energized; our sense is that continued scientific leadership, a promising pipeline, launches on the way, and a history of strong commercial delivery are going to fuel growth over the long term. Our commitment stands to keeping the Merck mission alive — by making R&D our sharper focus and by staying at the leading edge of research that saves lives, which will prove vital in solving for this pandemic along with other healthcare challenges. So we're glad you could be with us today. Stay safe and healthy, you and your family.
Operator
operatorThanks a lot, presenters, and once more, thanks to all of you for joining in. That brings today's call to a close, you're welcome to hang up now, take care of yourselves and enjoy a wonderful day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.